3,323 Shares in Medpace Holdings, Inc. $MEDP Purchased by PFA Pension Forsikringsaktieselskab

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position in Medpace, buying 3,323 shares in Q4 valued at approximately $1.89 million.
• Insider sale: President Jesse J. Geiger sold 31,707 shares on March 17 for about $14.44 million, reducing his ownership by 67.88%.
• Securities‑fraud class actions are being filed and solicited by multiple law firms, creating legal risk and analyst caution even as Medpace recently beat EPS estimates, grew revenue 26.5% year‑over‑year, and raised FY2026 guidance.

PFA Pension Forsikringsaktieselskab purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,323 shares of the company's stock, valued at approximately $1,890,000.

Other large investors also recently bought and sold shares of the company. Quent Capital LLC acquired a new position in shares of Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace during the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Finally, Quarry LP acquired a new stake in shares of Medpace in the 3rd quarter worth $35,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares of the company's stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 20.50% of the company's stock.

Medpace Trading Down 0.1%

Shares of NASDAQ MEDP opened at $417.02 on Tuesday. Medpace Holdings, Inc. has a twelve month low of $284.10 and a twelve month high of $628.92. The stock has a fifty day simple moving average of $468.91 and a 200-day simple moving average of $532.96. The stock has a market capitalization of $11.91 billion, a PE ratio of 26.21, a PEG ratio of 2.12 and a beta of 1.19.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts' consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analysts' expectations of $697.82 million. During the same period in the previous year, the firm posted $3.67 earnings per share. The company's revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: A recent bullish write-up summarizes a constructive investment thesis on Medpace that argues for continued revenue growth and margin resilience; this could support longer‑term investor sentiment. Is Medpace Holdings, Inc. (MEDP) A Good Stock To Buy Now?
• Neutral Sentiment: On April 22 Medpace reported an EPS beat and raised FY‑2026 EPS guidance to a range that implies continued profitability; that fundamental strength moderates downside risk from the legal headlines.
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for a securities‑fraud class action alleging the company and certain executives misled investors; such litigation can weigh on the stock via legal costs, management distraction and investor uncertainty. $MEDP Stock Drop Alert: Medpace Stock Plummeted 16% on News of Cancellation Rates – Investors Notified to Contact BFA Law about the Class Action
• Negative Sentiment: Multiple plaintiff firms (Bragar Eagel & Squire; Rosen; Faruqi & Faruqi; Schall; DJS; Bleichmar Fonti & Auld; others) are actively soliciting lead‑plaintiff candidates and reminding investors of deadlines — an indicator the litigation will proceed and attract attention. Examples: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ROSEN, A TOP RANKED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel
• Negative Sentiment: Another round of firm notices (Faruqi & Faruqi; Schall Law Firm; DJS Law Group) underscore active plaintiff interest and impending lead‑plaintiff deadlines (early June), keeping legal risk top‑of‑mind for shareholders. MEDP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
• Negative Sentiment: Analyst commentary has turned cautious in places — Baird and Truist flagged pressure or trimmed price targets — which can amplify selling pressure while litigation headlines persist. MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Levi & Korsinsky

Analyst Ratings Changes

A number of brokerages have issued reports on MEDP. Royal Bank Of Canada cut their target price on Medpace from $522.00 to $484.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. TD Cowen upgraded Medpace from a "sell" rating to a "hold" rating and lowered their price objective for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Barclays lowered their price objective on Medpace from $500.00 to $450.00 and set an "equal weight" rating for the company in a research report on Friday, April 24th. Finally, Weiss Ratings lowered Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $467.08.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.